v3.26.1
Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Revenue $ 56,698 $ 239,240 $ 196,212 $ 905,895
Cost of sales 14,246 15,325 44,941 29,439
Research and development expenses:        
Selling, general, and administrative expense 26,665 43,612 55,442 91,702
Other segment income (expense) 1,519      
Net income (loss) (53,387) 106,508 (62,878) 625,154
Reportable Segment        
Segment Reporting [Line Items]        
Revenue 56,698 239,240 196,212 905,895
Cost of sales 14,246 15,325 44,941 29,439
Research and development expenses:        
Employee and benefit expenses 30,820 36,149 68,875 76,060
Facility and other research and development expenses 15,968 22,048 34,013 42,668
Selling, general, and administrative expense 26,665 43,612 55,442 91,702
Other segment income (expense)   5,438 7,458 8,570
Net income (loss) (53,387) 106,508 (62,878) 625,154
Reportable Segment | Direct COVID-19 Vaccine        
Research and development expenses:        
Supplier finance programs 20,073 13,077 54,328 28,824
Reportable Segment | Direct CIC and influenza vaccines        
Research and development expenses:        
Supplier finance programs 703 7,117 3,556 19,621
Reportable Segment | Direct other vaccine development programs        
Research and development expenses:        
Supplier finance programs $ 3,129 $ 842 $ 5,393 $ 997